Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
FDA Knew Drugmaker Had Poor Record. It Waited Four Years to Inspect One Factory
FDA Knew Drugmaker Had Poor Record. It Waited Four Years to Inspect One Factory
GSK's $12 Billion Hengrui Pharma Partnership
GSK's $12 Billion Hengrui Pharma Partnership: A Catalyst for Pipeline Growth and Therapeutic Leadership Beyond 2031
MAIA Biotechnology Reports FDA's
MAIA Biotechnology Reports FDA's Fast Track Designation For Ateganosine
AI at the FDA: help or hindrance?
With the introduction of genAI tool Elsa at the FDA in June, the technology is playing a greater role in the medical device review process.
UK-India $4.8bn FTA poised to benefit medtech and pharma
The free trade agreement is expected to reduce regulatory burdens on UK exports to India and boost trade in the pharmaceutical and medical device industries.
Sun Pharma, Lupin, Dr. Reddy's
Sun Pharma, Lupin, Dr. Reddy's: Pharma stocks may see some pressure tomorrow; here is why
Lantheus Holdings Expands Alzheimer’s
Lantheus Holdings Expands Alzheimer’s Diagnostics Despite Recent Stock Dip
Novavax's H5N1
Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
Breaking News: FDA Approves the First Treatment for Moderate-to-Severe Chronic Hand Eczema
Today the eczema community is one step closer to having a new treatment option.
New class of chiral molecules offers strong stability for drug development
Scientists have created a new class of ultra-stable chiral molecules – a discovery that could lead to more precise drug design by preventing potentially harmful molecular “flipping” over time
Trump threatens 200% drug tariff as AstraZeneca leads $50 billion US investment
WASHINGTON (TNND) — President Donald Trump announced on Monday that British-Swedish drugmaker AstraZeneca will be investing $50 billion in the United States by 2030.
FDA Moving to Nonanimal Testing Methodologies in Preclinical Research
The plan first addresses monoclonal antibodies but could eventually be applied to all compounds seeking FDA approval.
33
34
35
36
37
38
39
40
41
